Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
| VOR Stock | USD 1.08 0.03 2.70% |
Slightly above 62% of Vor Biopharma's investor base is looking to short. The analysis of the overall investor sentiment regarding Vor Biopharma suggests that many traders are alarmed. Vor Biopharma's investing sentiment overview a quick insight into current market opportunities from investing in Vor Biopharma. Many technical investors use Vor Biopharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Vor |
Company to present trem-cel Mylotarg clinical data update at American Society of Hematology 2024 annual meetingHan Choi, M.D., LL.M, seasoned healthcare institutional investor, appointed as Chief Financial Officer CAMBRIDGE, Mass., Nov. 07, 2024 -- Vor Bio , a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2024, and provided a corporate update. We are pleased with our opera
Read at finance.yahoo.com
 |
Vor Biopharma Fundamental Analysis
We analyze Vor Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vor Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vor Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Vor Biopharma is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Vor Biopharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Vor Biopharma stock to make a market-neutral strategy. Peer analysis of Vor Biopharma could also be used in its relative valuation, which is a method of valuing Vor Biopharma by comparing valuation metrics with similar companies.
Peers
Vor Biopharma Related Equities
| STTK | Shattuck Labs | 10.92 | ||||
| VTYX | Ventyx Biosciences | 8.97 | ||||
| ERAS | Erasca | 6.20 | ||||
| ACLX | Arcellx | 5.59 | ||||
| LYRA | Lyra Therapeutics | 5.00 | ||||
| FHTX | Foghorn Therapeutics | 4.75 | ||||
| ACET | Adicet Bio | 4.65 | ||||
| DSGN | Design Therapeutics | 3.85 | ||||
| KYMR | Kymera Therapeutics | 3.64 | ||||
| KNSA | Kiniksa Pharmaceuticals | 3.31 | ||||
| NRIX | Nurix Therapeutics | 3.00 | ||||
| GLUE | Monte Rosa | 0.92 | ||||
| NUVL | Nuvalent | 0.09 | ||||
| EWTX | Edgewise Therapeutics | 0.83 | ||||
| AUTL | Autolus Therapeutics | 1.14 | ||||
| CGEM | Cullinan Oncology | 1.39 | ||||
| BOLT | Bolt Biotherapeutics | 2.08 | ||||
| DAWN | Day One | 4.03 |
Additional Tools for Vor Stock Analysis
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.